Boothbay Fund Management Increases Stake in Fulcrum Therapeutics

Hedge fund boosts ownership in biotech company by over 100% in Q3

Mar. 16, 2026 at 7:52am

Got story updates? Submit your updates here. ›

Boothbay Fund Management LLC increased its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 104.2% during the third quarter, according to a recent SEC filing. The hedge fund now owns 678,414 shares of the company's stock, representing 1.25% ownership.

Why it matters

Fulcrum Therapeutics is a clinical-stage biotech company focused on developing treatments for genetic diseases. The increase in Boothbay's stake suggests the fund sees significant potential in the company's pipeline and future prospects.

The details

According to the filing, Boothbay Fund Management purchased an additional 346,136 shares of Fulcrum Therapeutics during the third quarter, bringing its total position to 678,414 shares worth $6.24 million. This represents a 104.2% increase in the fund's ownership of the biotech company.

  • Boothbay Fund Management increased its stake in Fulcrum Therapeutics during the third quarter of 2026.

The players

Boothbay Fund Management LLC

A hedge fund that has increased its ownership stake in Fulcrum Therapeutics.

Fulcrum Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing treatments for genetic diseases.

Got photos? Submit your photos here. ›

The takeaway

Boothbay Fund Management's increased investment in Fulcrum Therapeutics suggests the hedge fund sees significant potential in the biotech company's pipeline and future prospects, despite the stock's recent volatility.